Spanish Breast Cancer Research Group

• NCT05982093

  Phase 2, Recruiting, 96 people, 8 Aug 2023

• Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)

  Collaborator, Phase 3, Recruiting, 220 people, 23 Aug 2022

• NCT05181462

  Collaborator, Phase 1/2, Completed, 117 people, 6 Jan 2022

• Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in PIK3CA-mutated HER2+ Advanced BC (ALPHABET)

  Phase 3, Terminated, 27 people, 1 Oct 2021

• NCT04595565

  Collaborator, Phase 3, Active, not recruiting, 1,332 people, 20 Oct 2020

• NCT04293393

  Phase 2, Active, not recruiting, 200 people, 3 Mar 2020

• NCT03609047

  Collaborator, Phase 2, Active, not recruiting, 366 people, 1 Aug 2018

• NCT03248427

  Phase 2, Completed, 106 people, 14 Aug 2017

• NCT02690480

  Phase 2, Status unknown, 189 people, 24 Feb 2016

• NCT02448420

  Phase 2, Completed, 73 people, 19 May 2015

• NCT02028507

  Phase 3, Completed, 693 people, 7 Jan 2014

• NCT01973660

  Phase 2, Completed, 151 people, 31 Oct 2013

• NCT01306942

  Phase 1/2, Completed, 37 people, 2 Mar 2011

• NCT01298193

  Phase 4, Completed, 212 people, 17 Feb 2011

• NCT00545077

  Phase 3, Completed, 380 people, 17 Oct 2007

• NCT00543127

  Phase 3, Terminated, 870 people, 12 Oct 2007

• NCT00432172

  Phase 2, Completed, 189 people, 7 Feb 2007

• NCT00258960

  Phase 2, Completed, 49 people, 28 Nov 2005

• NCT00130494

  Phase 3, Terminated, 97 people, 15 Aug 2005

• NCT00129935

  Phase 3, Completed, 1,384 people, 12 Aug 2005

Sources: clinicaltrials.gov